Results 1 to 10 of about 53,097 (209)

Imatinib and nilotinib are equally successful in achieving therapy-free remission. [PDF]

Blood Cancer J
Cheng F, Wang Y, Yang Y, Du X, Zhu Y, Weng J, Xu N, Huang J, Liu Z, Ren H, Zhao H, Zhu H, Jiang Q, Zhang Y, Li W.   +14 more
europepmc   +1 more source

Targeting STAT5A via CRISPR/Cas9 restores TKI sensitivity in resistant chronic myeloid leukemia cells. [PDF]

Med Oncol
Çelik B, Kiraz Y, Şahin Y, Tezcanlı Kaymaz B.   +3 more
europepmc   +1 more source

B-Lymphoblastic Leukemia With Isolated Central Nervous System Relapse Mimicking a Vestibular Schwannoma. [PDF]

Clin Case Rep
Ng JY, Lalloo ST, Milliken S, Polizzotto MN.   +3 more
europepmc   +1 more source

When precision medicine meets human behavior: limits of artificial intelligence in predicting imatinib adherence. [PDF]

J Gastrointest Oncol
Kanda T.
europepmc   +1 more source

Identification of MBT3T as a new effective therapeutic option in imatinib-resistant gastrointestinal stromal tumors (GISTs). [PDF]

J Exp Clin Cancer Res
Ravegnini G, Esposito D, Gorini F, Marforio TD, Coschina E, Benuzzi E, Simone A, Samaha A, Di Vito A, Rossi M, Hrelia P, Locatelli A, Calvaresi M, Facchinello N, Morigi R, Angelini S.   +15 more
europepmc   +1 more source

Transcriptional readthrough precedes alternative splicing programs triggered in CML cells by imatinib. [PDF]

Sci Adv
Podszywałow-Bartnicka P, Shine M, Lin J, Neugebauer KM.   +3 more
europepmc   +1 more source

A Ponatinib-Associated Transcriptomic Signature: Implications for Cardiovascular Toxicity. [PDF]

Int J Mol Sci
Kong J, Jang J, Kong JH, Lee T.
europepmc   +1 more source

A CML Patient with Unintentional Bosutinib Exposure During the First Trimester of Pregnancy [PDF]

Turk J Haematol
Küçükbaş Özönder GN, Terzi Demirsoy E, Mehtap Ö, Metli K.   +3 more
europepmc   +1 more source